Sentinel lymph node biopsy for patients with early-stage breast cancer

American Society of Clinical Oncology clinical practice guideline update

Gary H. Lyman, Sarah Temin*, Stephen B. Edge, Lisa A. Newman, Roderick R. Turner, Donald L. Weaver, Al B Benson III, Linda D. Bosserman, Harold J. Burstein, Hiram Cody, James Hayman, Cheryl L. Perkins, Donald A. Podoloff, Armando E. Giuliano

*Corresponding author for this work

Research output: Contribution to journalReview article

408 Citations (Scopus)

Abstract

Purpose: To provide evidence-based recommendations to practicing oncologists, surgeons, and radiation therapy clinicians to update the 2005 clinical practice guideline on the use of sentinel node biopsy (SNB) for patients with early-stage breast cancer. Methods: The American Society of Clinical Oncology convened an Update Committee of experts in medical oncology, pathology, radiation oncology, surgical oncology, guideline implementation, and advocacy. A systematic review of the literature was conducted from February 2004 to January 2013 in Medline. Guideline recommendations were based on the review of the evidence by Update Committee. Results: This guideline update reflects changes in practice since the 2005 guideline. Nine randomized clinical trials (RCTs) met systematic review criteria for clinical questions 1 and 2; 13 cohort studies informed clinical question 3. Recommendations: Women without sentinel lymph node (SLN) metastases should not receive axillary lymph node dissection (ALND). Women with one to two metastatic SLNs planning to undergo breast-conserving surgery with whole-breast radiotherapy should not undergo ALND (in most cases). Women with SLN metastases who will undergo mastectomy should be offered ALND. These three recommendation are based on RCTs. Women with operable breast cancer and multicentric tumors, with ductal carcinoma in situ (DCIS) who will undergo mastectomy, who previously underwent breast and/or axillary surgery, or who received preoperative/neoadjuvant systemic therapy may be offered SNB. Women who have large or locally advanced invasive breast cancer (tumor size T3/T4), inflammatory breast cancer, or DCIS (when breast-conserving surgery is planned) or are pregnant should not undergo SNB. These recommendations are based on cohort studies and/or informal consensus. In some cases, updated evidence was insufficient to update previous recommendations.

Original languageEnglish (US)
Pages (from-to)1365-1383
Number of pages19
JournalJournal of Clinical Oncology
Volume32
Issue number13
DOIs
StatePublished - May 1 2014

Fingerprint

Sentinel Lymph Node Biopsy
Practice Guidelines
Breast Neoplasms
Lymph Node Excision
Inflammatory Breast Neoplasms
Guidelines
Carcinoma, Intraductal, Noninfiltrating
Segmental Mastectomy
Mastectomy
Biopsy
Breast
Cohort Studies
Radiotherapy
Randomized Controlled Trials
Neoplasm Metastasis
Radiation Oncology
Neoadjuvant Therapy
Medical Oncology
Pathology
cyhalothrin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Lyman, Gary H. ; Temin, Sarah ; Edge, Stephen B. ; Newman, Lisa A. ; Turner, Roderick R. ; Weaver, Donald L. ; Benson III, Al B ; Bosserman, Linda D. ; Burstein, Harold J. ; Cody, Hiram ; Hayman, James ; Perkins, Cheryl L. ; Podoloff, Donald A. ; Giuliano, Armando E. / Sentinel lymph node biopsy for patients with early-stage breast cancer : American Society of Clinical Oncology clinical practice guideline update. In: Journal of Clinical Oncology. 2014 ; Vol. 32, No. 13. pp. 1365-1383.
@article{b3601c131f0645568a538e92fc1d6bd4,
title = "Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update",
abstract = "Purpose: To provide evidence-based recommendations to practicing oncologists, surgeons, and radiation therapy clinicians to update the 2005 clinical practice guideline on the use of sentinel node biopsy (SNB) for patients with early-stage breast cancer. Methods: The American Society of Clinical Oncology convened an Update Committee of experts in medical oncology, pathology, radiation oncology, surgical oncology, guideline implementation, and advocacy. A systematic review of the literature was conducted from February 2004 to January 2013 in Medline. Guideline recommendations were based on the review of the evidence by Update Committee. Results: This guideline update reflects changes in practice since the 2005 guideline. Nine randomized clinical trials (RCTs) met systematic review criteria for clinical questions 1 and 2; 13 cohort studies informed clinical question 3. Recommendations: Women without sentinel lymph node (SLN) metastases should not receive axillary lymph node dissection (ALND). Women with one to two metastatic SLNs planning to undergo breast-conserving surgery with whole-breast radiotherapy should not undergo ALND (in most cases). Women with SLN metastases who will undergo mastectomy should be offered ALND. These three recommendation are based on RCTs. Women with operable breast cancer and multicentric tumors, with ductal carcinoma in situ (DCIS) who will undergo mastectomy, who previously underwent breast and/or axillary surgery, or who received preoperative/neoadjuvant systemic therapy may be offered SNB. Women who have large or locally advanced invasive breast cancer (tumor size T3/T4), inflammatory breast cancer, or DCIS (when breast-conserving surgery is planned) or are pregnant should not undergo SNB. These recommendations are based on cohort studies and/or informal consensus. In some cases, updated evidence was insufficient to update previous recommendations.",
author = "Lyman, {Gary H.} and Sarah Temin and Edge, {Stephen B.} and Newman, {Lisa A.} and Turner, {Roderick R.} and Weaver, {Donald L.} and {Benson III}, {Al B} and Bosserman, {Linda D.} and Burstein, {Harold J.} and Hiram Cody and James Hayman and Perkins, {Cheryl L.} and Podoloff, {Donald A.} and Giuliano, {Armando E.}",
year = "2014",
month = "5",
day = "1",
doi = "10.1200/JCO.2013.54.1177",
language = "English (US)",
volume = "32",
pages = "1365--1383",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "13",

}

Lyman, GH, Temin, S, Edge, SB, Newman, LA, Turner, RR, Weaver, DL, Benson III, AB, Bosserman, LD, Burstein, HJ, Cody, H, Hayman, J, Perkins, CL, Podoloff, DA & Giuliano, AE 2014, 'Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update', Journal of Clinical Oncology, vol. 32, no. 13, pp. 1365-1383. https://doi.org/10.1200/JCO.2013.54.1177

Sentinel lymph node biopsy for patients with early-stage breast cancer : American Society of Clinical Oncology clinical practice guideline update. / Lyman, Gary H.; Temin, Sarah; Edge, Stephen B.; Newman, Lisa A.; Turner, Roderick R.; Weaver, Donald L.; Benson III, Al B; Bosserman, Linda D.; Burstein, Harold J.; Cody, Hiram; Hayman, James; Perkins, Cheryl L.; Podoloff, Donald A.; Giuliano, Armando E.

In: Journal of Clinical Oncology, Vol. 32, No. 13, 01.05.2014, p. 1365-1383.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Sentinel lymph node biopsy for patients with early-stage breast cancer

T2 - American Society of Clinical Oncology clinical practice guideline update

AU - Lyman, Gary H.

AU - Temin, Sarah

AU - Edge, Stephen B.

AU - Newman, Lisa A.

AU - Turner, Roderick R.

AU - Weaver, Donald L.

AU - Benson III, Al B

AU - Bosserman, Linda D.

AU - Burstein, Harold J.

AU - Cody, Hiram

AU - Hayman, James

AU - Perkins, Cheryl L.

AU - Podoloff, Donald A.

AU - Giuliano, Armando E.

PY - 2014/5/1

Y1 - 2014/5/1

N2 - Purpose: To provide evidence-based recommendations to practicing oncologists, surgeons, and radiation therapy clinicians to update the 2005 clinical practice guideline on the use of sentinel node biopsy (SNB) for patients with early-stage breast cancer. Methods: The American Society of Clinical Oncology convened an Update Committee of experts in medical oncology, pathology, radiation oncology, surgical oncology, guideline implementation, and advocacy. A systematic review of the literature was conducted from February 2004 to January 2013 in Medline. Guideline recommendations were based on the review of the evidence by Update Committee. Results: This guideline update reflects changes in practice since the 2005 guideline. Nine randomized clinical trials (RCTs) met systematic review criteria for clinical questions 1 and 2; 13 cohort studies informed clinical question 3. Recommendations: Women without sentinel lymph node (SLN) metastases should not receive axillary lymph node dissection (ALND). Women with one to two metastatic SLNs planning to undergo breast-conserving surgery with whole-breast radiotherapy should not undergo ALND (in most cases). Women with SLN metastases who will undergo mastectomy should be offered ALND. These three recommendation are based on RCTs. Women with operable breast cancer and multicentric tumors, with ductal carcinoma in situ (DCIS) who will undergo mastectomy, who previously underwent breast and/or axillary surgery, or who received preoperative/neoadjuvant systemic therapy may be offered SNB. Women who have large or locally advanced invasive breast cancer (tumor size T3/T4), inflammatory breast cancer, or DCIS (when breast-conserving surgery is planned) or are pregnant should not undergo SNB. These recommendations are based on cohort studies and/or informal consensus. In some cases, updated evidence was insufficient to update previous recommendations.

AB - Purpose: To provide evidence-based recommendations to practicing oncologists, surgeons, and radiation therapy clinicians to update the 2005 clinical practice guideline on the use of sentinel node biopsy (SNB) for patients with early-stage breast cancer. Methods: The American Society of Clinical Oncology convened an Update Committee of experts in medical oncology, pathology, radiation oncology, surgical oncology, guideline implementation, and advocacy. A systematic review of the literature was conducted from February 2004 to January 2013 in Medline. Guideline recommendations were based on the review of the evidence by Update Committee. Results: This guideline update reflects changes in practice since the 2005 guideline. Nine randomized clinical trials (RCTs) met systematic review criteria for clinical questions 1 and 2; 13 cohort studies informed clinical question 3. Recommendations: Women without sentinel lymph node (SLN) metastases should not receive axillary lymph node dissection (ALND). Women with one to two metastatic SLNs planning to undergo breast-conserving surgery with whole-breast radiotherapy should not undergo ALND (in most cases). Women with SLN metastases who will undergo mastectomy should be offered ALND. These three recommendation are based on RCTs. Women with operable breast cancer and multicentric tumors, with ductal carcinoma in situ (DCIS) who will undergo mastectomy, who previously underwent breast and/or axillary surgery, or who received preoperative/neoadjuvant systemic therapy may be offered SNB. Women who have large or locally advanced invasive breast cancer (tumor size T3/T4), inflammatory breast cancer, or DCIS (when breast-conserving surgery is planned) or are pregnant should not undergo SNB. These recommendations are based on cohort studies and/or informal consensus. In some cases, updated evidence was insufficient to update previous recommendations.

UR - http://www.scopus.com/inward/record.url?scp=84900421315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900421315&partnerID=8YFLogxK

U2 - 10.1200/JCO.2013.54.1177

DO - 10.1200/JCO.2013.54.1177

M3 - Review article

VL - 32

SP - 1365

EP - 1383

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 13

ER -